GNH USA

Europe — EMA

Lapatinib Stada

GNH USA supplies Lapatinib Stada (Lapatinib), a tyrosine kinase inhibitor for HER2-positive metastatic breast and gastric cancer.

Lapatinib

Request sourcing

1
Pack/s

What is Lapatinib?

Lapatinib, the active ingredient in Lapatinib Stada, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats HER2‑positive metastatic breast cancer and HER2‑positive metastatic gastric cancer.

GNH USA supplies Lapatinib Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

What is Lapatinib used for?

Lapatinib is a targeted therapy that acts on HER2‑driven cancers. - HER2‑positive metastatic breast cancer: improves progression‑free survival when used with trastuzumab and capecitabine. - HER2‑positive metastatic gastric cancer: delays disease progression in combination regimens. - Combination therapy with trastuzumab and capecitabine: enhances antitumor activity in HER2‑positive disease.

What are the side effects of Lapatinib?

Lapatinib may cause a range of adverse reactions.

Common Side Effects: - Diarrhea: frequent loose stools. - Rash: skin irritation, often on the trunk. - Nausea: feeling of sickness, may lead to vomiting. - Fatigue: persistent tiredness. - Hand‑foot syndrome: redness or swelling of palms and soles.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac dysfunction: reduced left ventricular ejection fraction. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Interstitial lung disease: breathing difficulties, cough. - QT interval prolongation: risk of cardiac arrhythmias.

What precautions apply to Lapatinib?

Before initiating therapy, clinicians should consider several safety measures. - Cardiac monitoring: assess baseline and periodic ejection fraction. - Hepatic function: check liver enzymes before and during treatment. - Pregnancy avoidance: contraindicated; advise effective contraception. - Drug interactions: review concomitant CYP3A4 modulators. - Dose adjustments: consider in patients with hepatic impairment. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

What does Lapatinib interact with?

Lapatinib can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase toxicity. - Strong CYP3A4 inducers (e.g., rifampicin): may reduce efficacy. - QT‑prolonging agents (e.g., sotalol): increase risk of arrhythmia.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): monitor INR. - Digoxin: watch for altered plasma levels. - Hormonal contraceptives: efficacy may be reduced. - Antacids or proton‑pump inhibitors: may affect absorption.

Frequently asked questions

What conditions is Lapatinib Stada used to treat?+
Lapatinib Stada is indicated for HER2‑positive metastatic breast cancer and HER2‑positive metastatic gastric cancer. It is used as part of combination regimens to improve disease control in patients whose tumors overexpress the HER2 protein.
How does Lapatinib work in the body?+
Lapatinib blocks the intracellular tyrosine kinase activity of EGFR and HER2 receptors. This inhibition stops downstream signaling pathways that drive cell growth and survival, thereby slowing or stopping the proliferation of HER2‑driven cancer cells.
What is the usual dose of Lapatinib Stada?+
The specific dose of Lapatinib Stada is determined by the prescribing physician based on the patient’s clinical condition, treatment regimen, and other individual factors. Dosage instructions are provided on the prescription label.
Is Lapatinib safe to use during pregnancy or breastfeeding?+
Lapatinib’s safety in pregnancy and lactation has not been established. It is generally contraindicated in pregnant women, and breastfeeding is not recommended while on therapy. Women of child‑bearing potential should use effective contraception.
How do I order Lapatinib Stada from GNH USA?+
To order Lapatinib Stada, submit an enquiry on the product page at gnh-usa.com with the required quantity. GNH USA supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.
How does Lapatinib compare with other HER2‑targeted therapies?+
Lapatinib is a small‑molecule tyrosine kinase inhibitor that targets both EGFR and HER2 intracellular domains, whereas agents like trastuzumab are monoclonal antibodies that bind the extracellular HER2 domain. Lapatinib can be combined with trastuzumab and chemotherapy for synergistic effects, offering an oral alternative to injectable biologics.
What are the recommended storage conditions for Lapatinib Stada?+
Lapatinib Stada should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not store in a bathroom or other humid environments.
How is Lapatinib Stada administered to patients?+
Lapatinib Stada is taken orally, usually once daily, with or without food as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not crushed or chewed.
What are the most serious risks associated with Lapatinib therapy?+
Serious risks include liver toxicity, cardiac dysfunction (reduced left‑ventricular ejection fraction), severe skin reactions such as Stevens‑Johnson syndrome, interstitial lung disease, and QT‑interval prolongation, which can lead to dangerous heart rhythms.
Who should not use Lapatinib Stada?+
Patients with known hypersensitivity to lapatinib or any of its excipients, those with uncontrolled cardiac disease, severe hepatic impairment, or who are pregnant should not use Lapatinib Stada. Clinicians should evaluate each patient’s medical history before initiating therapy.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Lapatinib
Route
Oral Use
Manufacturer
Stada M&d S.R.L.
Origin
EU

Related products

TYKERB 250 mg/1

TYKERB 250 mg/1

Lapatinib · 250 mg

Tykerb
TABLET
Novartis Pharmaceuticals Corporation
USA
Lapatinib 250 mg/1

Lapatinib 250 mg/1

Lapatinib · 250 mg

Lapatinib
TABLET, FILM COATED
Teva Pharmaceuticals, Inc.
USA
Brastib

Brastib

Lapatinib

Stada Arzneimittel Ag
EU
Brastib

Brastib

Lapatinib

Stada Arzneimittel Ag
EU